TIGIT and neoplasm: Hence, we assessed the tumor cell expression of four distinct immune checkpoint ligands; PD-L1, CD80, GAL-9, and PVR, which interact with the clinically relevant receptors PD-1, CTLA-4, TIM3, and TIGIT on T cells.